Maria Laura F.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 2 Study of Iadademstat in Patients with Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
Data & Insights
Has run more than one trial at 132 of 259 partner sites.
Specializations
Primary Myelofibrosis Research
This investigator specializes in treating primary myelofibrosis and its various manifestations, with particular focus on developing combination therapeutic approaches. Their research encompasses novel treatment strategies for patients who have not previously received JAK inhibitor therapy.
- Novel therapeutic combinations
- JAK inhibitor-based treatments
- Spleen volume reduction therapies
Secondary Myelofibrosis Studies
The investigator conducts extensive research in secondary myelofibrosis, including conditions that develop from other blood disorders. Their work specifically addresses post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
- Post-PV myelofibrosis treatments
- Post-ET myelofibrosis interventions
- Combination therapy approaches
Advanced Hematological Disorders
Their expertise extends to treating complex hematological conditions, with particular emphasis on polycythemia vera. The investigator focuses on developing treatments for patients with specific therapeutic needs, including those with transfusion-dependent myelofibrosis.
- Anemia management strategies
- Symptom score improvement
- Novel therapeutic agents
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.